Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure

Advanced Epithelial Ovarian Cancer (EOC) patients frequently relapse by 24 months and develop resistant disease. Research on EOC therapies relies on cancer cell lines established decades ago making Patient Derived Xenografts (PDX) attractive models, because they are faithful representations of the o...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Colombo, Pierre-Emmanuel, du Manoir, Stanislas, Orsetti, Béatrice, Bras-Gonçalves, Rui, Lambros, Mario B., MacKay, Alan, Nguyen, Tien-Tuan, Boissiére, Florence, Pourquier, Didier, Bibeau, Frédéric, Reis-Filho, Jorge S., Theillet, Charles
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2015
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4695063/
https://ncbi.nlm.nih.gov/pubmed/26334103
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items